The Microbiome and Cancer Treatment

Dr. Aggarwal is currently a senior postdoctoral fellow at the MD Anderson Cancer Center, Texas, USA. She completed Ph.D. from AIIMS, New Delhi under supervision of Prof. S. N. Das. During PhD, wherein she successfully addressed various aspects of local immunopathology in oral squamous cell carcinoma (OSCC). She published dozens of articles and several book chapters. She is an editorial board member of several indexed reputed international journals. Garima Malik has completed her B. Pharmacy from Vaish Institute of Pharmaceutical Education and Research, Rohtak, and an M.Pharmacy from Chandigarh College of Pharmacy, Landran. She has more than 3 years of experience as an Assistant Professor in the Department of Pharmaceutics. Currently, she is working as an Assistant Professor at M.M College of Pharmacy, Maharishi Markandeshwar University, Mullana, Ambala, India. Ms Garima had about 1.5 years of experience as an officer in the Quality control department at Zenacts Pharma Manimajra, Chandigarh. Her M.Pharmacy project focused on the topic of “Preparation and evaluation of Fusidic acid loaded transferosomes amalgamated with gel for the management of burn wound infection”. She has published more than 10 publications, including 1 Patent, and 5 book chapters. Her area of interest is nanotechnology, hydrogels, biomaterials, and their application in drug delivery. Arun Kumar Singh is an Assistant Professor in the Department of Pharmacy at University School of Pharmaceutical Sciences, Rayat Bahra University V.P.O. Sahauran , India. He completed his M.Pharm in Pharmaceutics from Galgotias University, Greater Noida. His research interests include nano-formulation, blockchain, IoT, machine learning, artificial intelligence, big data analytics, cancer biology, and neuroscience. He has contributed to academic books and book chapters and has published review articles in the areas of pharmaceutical sciences and healthcare technology. His work focuses on interdisciplinary approaches integrating pharmaceutical research with emerging digital and computational technologies. Dr. Meenakshi Dhanawat is an Associate Professor at the Amity Institute of Pharmacy, Amity University Haryana, with over 18 years of experience in Pharmaceutical Sciences and Medicinal Chemistry. She completed her Master's degree at NIPER, Mohali, focusing on glycosylamino acids, and earned her Ph.D. from IIT-BHU, Varanasi, investigating CNS drug delivery targeting 5HT1A/2A receptors. Her research encompasses synthetic and heterocyclic chemistry, nanotechnology, drug delivery systems, prodrug design, complexation, polymer chemistry, and herbal drug extraction. Dr. Dhanawat has received notable international recognition, including a travel grant from the AAPS Drug Delivery and Development section for the 2010 National Biotechnology Conference in California, and international travel grants from DBT and DST, Government of India, for conferences in California and Munich. Her distinguished honors include the Rajiv Gandhi National Fellowship, affirming her sustained contributions to pharmaceutical research and academic excellence.

• 1. Understanding the Microbiome: Microbiome and Immune System Interactions2. The Microbiome: Its Impact on Cancer Development and Therapeutic Responses3. Microbiome Dynamics in Cancer Treatment: Impact of Chemotherapy on the Microbiome4. Microbiome as a Modulator of Immunotherapy: Synergistic Effects of the Microbiome in Immunotherapy5. Microbiome-Based Strategies to Overcome Chemoresistance: Probiotics and Prebiotics in Cancer Therapy6. Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy7. The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy8. Cancer pharmacomicrobiomics: targeting microbiota to optimize cancer therapy outcomes9. Gut microbiome in modulating immune checkpoint inhibitors10. Microbiome-based diagnostics and biomarkers: The search for mechanistic connections11. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors12. Current challenges and Future Prospects for Microbiome Research in Cancer Treatment